Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

GERSHENSON DAVID M. MD; COPELAND, LARRY J. MD; KAVANAGH, JOHN J. MD; STRINGER, C. ALLEN MD; SAUL, PATTON B. MD; WHARTON, J. TAYLOR MD
Obstetrics & Gynecology: November 1987
Article: PDF Only
Buy

From September 1981 until June 1986, eight patients with metastatic ovarian stromal tumors were entered into a prospective phase I1 study to determine the efficacy of a chemotherapy regimen combining cisplatin, doxorubicin, and cyclophosphamide. Patients received cisplatin 40–50 mg/m2 intravenously (IV), doxorubicin 40–50 mg/m2 IV, and cyclophosphamide 400–500 mg/m2 IV, all on day 1 every 28 days. The median age was 43 years (range 24–65 years). Two patients had stage I1 disease, one had stage 111, and five had recurrent disease (original stage: four stage I and one stage 111). The median number of chemotherapy cycles was six (range four to 14). Three patients (38%) had a complete response to therapy (two confirmed by second-look laparotomy), and two patients (25%) achieved a partial response (one verified by second-look laparotomy). The overall response rate was 63%. Toxicity was minimal. Four patients are disease-free at 13+ to 48+ months, one patient is alive with disease at six+ months, and three patients are dead of tumor at four, 17, and 36 months from the start of chemotherapy. These results indicate that the combination of cisplatin, doxorubicin, and cyclophosphamide has modest activity in the treatment of metastatic ovarian stromal tumor.

© 1987 The American College of Obstetricians and Gynecologists